Background: The high prevalence of psoriasis, its multifactorial nature, the systemic nature of pathological processes, severe comorbidities, psychological disturbances in patients, and reduced quality of life make selection of a proper psoriasis treatment regimen a challenging task and necessitate broadening the capabilities of systemic therapy of dermatosis. Objective: To analyze the clinical effectiveness and safety of systemic therapy of psoriasis with apremilast. Material and Methods. Seven patients having moderate and severe plaque psoriasis and psoriatic arthritis were examined and treated. The intensity of the pathological process in patients’ skin, the disease dynamics, and treatment effectiveness in patients with psoriasis were evaluated using the PASI, BSA, IGA, and VAS scores. The effect of dermatosis on quality of life was assessed using the DLQI score. Results. High clinical efficacy and safety of systemic treatment with apremilast was proved. The findings demonstrate that apremilast is an effective drug for treating patients with moderate and severe plaque psoriasis and psoriatic arthritis. Apremilast safety and the low risk of drug—drug interactions allow using this drug to treat psoriasis in elderly patients and individuals with comorbidities associated with psoriasis.